


Hereditary Angioedema Therapeutics Market Size, Growth Drivers and Global Forecast 2034 | At a Thriving CAGR of 17.72%

High Cost of Therapies: Advanced biologic treatments remain expensive, limiting access for some patients.

US, NY, UNITED STATES, March 11, 2025 /EINPresswire.com/ -- Hereditary Angioedema Therapeutics Market Poised for Growth Amid Rising Demand for Advanced Treatment Options



Market Overview

The global <u>Hereditary Angioedema (HAE) Therapeutics Market valued</u> at USD 6.71 billion in 2024, is projected to witness significant expansion, reaching USD 34.3 billion by 2034, at a CAGR of 17.72%. This growth is driven by increasing awareness, advancements in targeted therapies, and the rising prevalence of hereditary angioedema.

What is Hereditary Angioedema?

Hereditary Angioedema (HAE) is a rare genetic disorder characterized by recurrent episodes of severe swelling in different body parts, including the extremities, gastrointestinal tract, and airways. It is caused by deficiencies or dysfunctions of C1-inhibitor proteins, leading to excessive fluid leakage from blood vessels.

Get your copy now by clicking here:

https://www.marketresearchfuture.com/sample_request/12163

Key Companies in the HAE Therapeutics Market:

Takeda Pharmaceutical CSL Behring Sanofi BioCryst Pharmaceuticals, Inc Pharvaris B.V. Ionis Pharmaceuticals, Inc Pharming Group N.V. KalVista Pharmaceuticals, Inc IBio, Inc. BioMarin Pharmaceutical Inc Major Developments in 2025

Leading pharmaceutical companies and research institutions are making significant advancements in HAE therapies. Notable innovations include gene therapies, long-acting prophylactic treatments, and next-generation monoclonal antibodies.

One of the most anticipated developments is the emergence of CRISPR-based gene editing therapies, offering potential curative solutions for hereditary angioedema patients.

Market Drivers

Rising Awareness & Diagnosis Rates: Increased efforts to improve early diagnosis and patient education are fueling market growth.

Advancements in Treatment Options: Development of plasma-derived therapies, small-molecule inhibitors, and gene therapy is revolutionizing HAE treatment.

Growing Investment in Rare Disease Research: Rising funding from pharmaceutical companies and government initiatives is accelerating drug development.

Increase in FDA & EMA Approvals: Regulatory approvals for newer, more effective HAE treatments are driving market expansion. Challenges Ahead

Despite promising growth, the market faces challenges such as:

High Cost of Therapies: Advanced biologic treatments remain expensive, limiting access for some patients.

Limited Patient Population: As a rare disease, the number of eligible patients is relatively small. Regulatory Hurdles: Strict approval processes for new biologics and gene therapies pose market entry challenges.

Buy it now by visiting here:

https://www.marketresearchfuture.com/checkout?currency=one_user-USD&report_id=12163

Hereditary Angioedema Therapeutics Market Segmentation

Hereditary Angioedema Therapeutics Type Outlook

Type I Type II Hereditary Angioedema Drug Class Outlook

C1 Esterase Inhibitor Selective Bradykinin B2 Receptor Antagonist Kallikrein Inhibitor Others Hereditary Angioedema Therapeutics Treatment Outlook

Prophylaxis Long-term Prophylaxis Short-term Prophylaxis On-demand Hereditary Angioedema Therapeutics Route of Administration Outlook

Intravenous Subcutaneous Oral Hereditary Angioedema Therapeutics Distribution Channel Outlook

Hospital Pharmacy Retail Pharmacy Online Pharmacy Hereditary Angioedema Therapeutics Regional Outlook

North America

US

Canada Europe Germany France UK Italy Spain Rest of Europe Asia-Pacific

China Japan India Australia South Korea Rest of Asia-Pacific Rest of the World

Middle East Africa Latin America Regional Analysis

North America: Dominates the market due to strong healthcare infrastructure, high diagnosis rates, and robust R&D investments.

Europe: Benefits from government-funded rare disease research programs and early adoption of advanced therapies.

Asia-Pacific (APAC): Projected to see rapid growth, driven by rising healthcare spending, increasing awareness, and improving diagnostic capabilities.

South America & Middle East & Africa (MEA): Steady growth expected due to expanding access to HAE treatments and improving medical infrastructure.

Recent Industry Developments

Takeda (January 2025) expanded its HAE drug portfolio by launching a next-generation monoclonal antibody therapy.

Pharming Group (March 2025) introduced a new subcutaneous C1-inhibitor therapy with extended half-life.

BioCryst Pharmaceuticals (June 2025) received FDA approval for an oral kallikrein inhibitor for HAE prophylaxis.

Looking Ahead

Industry analysts predict that the global hereditary angioedema therapeutics market will continue to expand as novel biologics, gene therapies, and AI-driven drug discovery gain momentum. Increased investments in personalized medicine and rare disease treatments will drive future market growth.

For healthcare providers and patients, these advancements offer more effective, long-term solutions to manage and potentially cure hereditary angioedema. As research progresses, HAE therapeutics are expected to revolutionize the management of this rare disorder.

Related MRFR Reports with Full Detailed Analysis:

Airway Clearance Devices Market- <u>https://www.marketresearchfuture.com/reports/airway-clearance-devices-market-31304</u> Allergy Diagnostic Market- <u>https://www.marketresearchfuture.com/reports/allergy-diagnostic-market-42041</u> Alzheimer's Drugs Market- <u>https://www.marketresearchfuture.com/reports/alzheimer-s-drugs-market-43601</u> Ambulance Services Market- <u>https://www.marketresearchfuture.com/reports/ambulance-services-market-42948</u> Ambulatory EHR Market- <u>https://www.marketresearchfuture.com/reports/ambulatory-ehr-market-8876</u> Market Research Future Market Research Future +1 855-661-4441 email us here Visit us on social media:

Facebook X

LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/792763480

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2025 Newsmatics Inc. All Right Reserved.